Choose a language and wait for the translated text.
Alembic Pharmaceuticals has received final approval from the US FDA for its Binimetinib tablets, intended for lung cancer treatment. These tablets are therapeutically equivalent to Array BioPharma Inc.'s Mektovi. As a first ANDA applicant, Alembic will benefit from 180 days of exclusivity for both the 15 mg and 45 mg dosages.
Alembic Pharma receives USFDA approval for lung cancer drug | PharmaVoice